Cognitive disorders are frequently found during late-life depression (LLD). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research
27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
With the unprecedented aging of the world's population, the number of elderly patients with depression is expected to increase. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Late-life depression is frequently associated with cognitive impairment. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
41/100
in multi-adjusted models, relative to individuals without depression, those with major (β per year: 0.33, 95% confidence interval [CI]: 0.06-0.61) and subsyndromal depression (β per year: 0.21, 95%CI: 0.12-0.30) experienced an accelerated rate of somatic multimorbidity accumulation, whereas those with minor depression did not. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Late-life depression (LLD) is associated with an increased risk of all-cause dementia and may involve Alzheimer's disease pathology. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In older age, frailty is a detrimental transitional status of the aging process featuring an increased susceptibility to stressors defined by a clinical reduction of homoeostatic reserves. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Individuals with unipolar depressive disorder (UDD) are having an increased risk of death and development of dementia in later life. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
A new Geriatric Depression Scale (GDS) designed specifically for rating depression in the elderly was tested for reliability and validity and compared with the Hamilton Rating Scale for Depression (HRS-D) and the Zung Self-Rating Depression Scale (SDS). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The pattern is manifested in one or more of the following: a) engaging in repetitive sexual activities has become a central focus of the person's life to the point of neglecting health and personal care or other interests, activities and responsibilities; b) the person has made numerous unsuccessful efforts to control or significantly reduce repetitive sexual behaviour; c) the person continues to engage in repetitive sexual behaviour despite adverse consequences (e.g., repeated relationship disruption, occupational consequences, negative impact on health); or d) the person continues to engage in repetitive sexual behaviour even when he/she derives little or no satisfaction from it. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Major depressive disorder (MDD) has until recently been conceptualized as an episodic disorder associated with 'chemical imbalances' but no permanent brain changes. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Depression is a frequent cause of morbidity in surgery patients suffering from a wide range of conditions. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
They concluded that their results “challenge our understanding of major depression as a homogeneous categorical entity”. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
At baseline, 211 (3.6%) of the women had 6 or more depressive symptoms. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
To elucidate an involvement of amyloid dysmetabolism in the pathophysiology of depression, we investigated associations of plasma amyloid-β (Aβ) levels with Alzheimer's disease-related changes in neuroimaging and cognitive dysfunction in patients with late-life depression. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Lithium as a mood stabilizer has been used as the standard pharmacological treatment for Bipolar Disorder (BD) for more than 60 years. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The history of medical and psychiatric use of lithium dates back to more than one and a half-century ago. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Lithium-based medications are used successfully to treat many mental disorders, including bipolar disorder and Alzheimer's disease. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This article covers current research on the relationship between depression and cognitive impairment in older adults. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Three major neurobiological features shared by LLD and AD include neurodegeneration, disruption to cerebrovascular functioning, and increased levels of neuroinflammation. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This article covers current research on the relationship between depression and cognitive impairment in older adults. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
We then review new research on moderators of clinical response and how to use the information for improved efficacy. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
This article appraises several facets of the linkage between depression and cognitive impairment, including dementia, mild cognitive impairment, and vascular dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
A number of biological and clinical characteristics typical of late life depression (LLD) have been suggested by recent research findings. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Although cognitive and functional impairment are the hallmark features of Alzheimer's disease (AD), neuropsychiatric symptoms associated with AD account for increased rates of disability and profoundly impact the quality of life of both patients and their caregivers. 2 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Major depressive disorder in the elderly-or late-life depression (LLD)-is one of the most common mental illnesses in the aging population. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
From across this tag
6 of the 139 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 6. The same 6 appear here every time.
- Low MoCA performances correlate with suicidal ideation in late-life depression
- Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression
- Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults
- The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders
- Differences in Odor Identification in Early-Onset and Late-Onset Depression
- Trace Lithium for Suicide Prevention and Dementia Prevention: A Qualitative Review
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →